| 2019-TOPP-68428 | |
| Researchers at Purdue University have developed a prodrug form of the peptide hormone, human calcitonin, to increase its effectiveness as an osteoporosis treatment. In humans, calcitonin is the hormone responsible for normal calcium homeostasis. When prescribed to osteoporosis patients, calcitonin inhibits bone resorption resulting in increased bone mass. Unfortunately, human calcitonin undergoes fibrillation in aqueous solution leading to reduced efficacy when used as a therapeutic. As a substitute, osteoporosis patients are prescribed salmon calcitonin which does not fibrillate as rapidly but suffers from low potency and immunotoxicity. To decrease the fibrillation propensity and increase the therapeutic benefit of human calcitonin, Purdue researchers phosphorylated specific amino acid residues. This modification's ability to inhibit fibril formation was validated in comparison to the unphosphorylated calcitonin through thioflavin T- fluorescence, hydrogen-deuterium exchange mass spectrometry, and circular dichroism. This prodrug approach will increase the therapeutic potential of human calcitonin, promising a more effective option to replace salmon calcitonin for osteoporosis and related disorders. Advantages: -Stable solution of human calcitonin -Higher potency than salmon calcitonin -Less toxicity than salmon calcitonin Potential Applications: -Drug Development -Osteoporosis Treatment -Hypercalcemia Treatment |
|
|
|
|
Mar 26, 2021
PCT-Gov. Funding
WO
(None)
(None)
Mar 30, 2020
Provisional-Gov. Funding
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
